Matches in SemOpenAlex for { <https://semopenalex.org/work/W1189663539> ?p ?o ?g. }
- W1189663539 endingPage "4142" @default.
- W1189663539 startingPage "4136" @default.
- W1189663539 abstract "Based on lead compound 1, which was discovered from a high-throughput screen, a series of PI3Kα/mTOR inhibitors were evaluated that contained an imidazo[1,2-a]pyridine as a core replacement for the benzimidazole contained in 1. By exploring various ring systems that occupy the affinity pocket, two fragments containing a methoxypyridine were identified that gave <100 nM potency toward PI3Kα in enzyme and cellular assays with moderate stability in rat and human liver microsomes. With the two methoxypyridine groups selected to occupy the affinity pocket, analogs were prepared with various fragments intended to occupy the ribose pocket of PI3Kα and mTOR. From these analogs, tertiary alcohol 18 was chosen for in vivo pharmacodynamic evaluation based on its potency in the PI3Kα cellular assay, microsomal stability, and in vivo pharmacokinetic properties. In a mouse liver pharmacodynamic assay, compound 18 showed 56% inhibition of HFG-induced AKT (Ser473) phosphorylation at a 30 mg/kg dose." @default.
- W1189663539 created "2016-06-24" @default.
- W1189663539 creator A5003543491 @default.
- W1189663539 creator A5010906992 @default.
- W1189663539 creator A5013507207 @default.
- W1189663539 creator A5015046857 @default.
- W1189663539 creator A5017725600 @default.
- W1189663539 creator A5019502209 @default.
- W1189663539 creator A5022335574 @default.
- W1189663539 creator A5032337429 @default.
- W1189663539 creator A5033334328 @default.
- W1189663539 creator A5036762272 @default.
- W1189663539 creator A5037958863 @default.
- W1189663539 creator A5041017678 @default.
- W1189663539 creator A5049605524 @default.
- W1189663539 creator A5049963981 @default.
- W1189663539 creator A5050487837 @default.
- W1189663539 creator A5053060128 @default.
- W1189663539 creator A5059234004 @default.
- W1189663539 date "2015-10-01" @default.
- W1189663539 modified "2023-10-16" @default.
- W1189663539 title "The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors" @default.
- W1189663539 cites W1527478027 @default.
- W1189663539 cites W1969292035 @default.
- W1189663539 cites W1971333358 @default.
- W1189663539 cites W1981811774 @default.
- W1189663539 cites W1984703406 @default.
- W1189663539 cites W1995169797 @default.
- W1189663539 cites W2001889835 @default.
- W1189663539 cites W2008339578 @default.
- W1189663539 cites W2009886463 @default.
- W1189663539 cites W2014390355 @default.
- W1189663539 cites W2018153260 @default.
- W1189663539 cites W2024441913 @default.
- W1189663539 cites W2035016671 @default.
- W1189663539 cites W2038822025 @default.
- W1189663539 cites W2044484262 @default.
- W1189663539 cites W2046246946 @default.
- W1189663539 cites W2054917860 @default.
- W1189663539 cites W2080100938 @default.
- W1189663539 cites W2092480028 @default.
- W1189663539 cites W2118262694 @default.
- W1189663539 cites W2124593509 @default.
- W1189663539 cites W2127789666 @default.
- W1189663539 cites W2128855114 @default.
- W1189663539 cites W2129172946 @default.
- W1189663539 cites W2137061677 @default.
- W1189663539 cites W2153607816 @default.
- W1189663539 cites W2154692501 @default.
- W1189663539 cites W2172145283 @default.
- W1189663539 cites W2339308294 @default.
- W1189663539 cites W2388163742 @default.
- W1189663539 cites W4250636261 @default.
- W1189663539 cites W47987147 @default.
- W1189663539 doi "https://doi.org/10.1016/j.bmcl.2015.08.016" @default.
- W1189663539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26298499" @default.
- W1189663539 hasPublicationYear "2015" @default.
- W1189663539 type Work @default.
- W1189663539 sameAs 1189663539 @default.
- W1189663539 citedByCount "19" @default.
- W1189663539 countsByYear W11896635392016 @default.
- W1189663539 countsByYear W11896635392017 @default.
- W1189663539 countsByYear W11896635392018 @default.
- W1189663539 countsByYear W11896635392019 @default.
- W1189663539 countsByYear W11896635392020 @default.
- W1189663539 countsByYear W11896635392021 @default.
- W1189663539 countsByYear W11896635392022 @default.
- W1189663539 countsByYear W11896635392023 @default.
- W1189663539 crossrefType "journal-article" @default.
- W1189663539 hasAuthorship W1189663539A5003543491 @default.
- W1189663539 hasAuthorship W1189663539A5010906992 @default.
- W1189663539 hasAuthorship W1189663539A5013507207 @default.
- W1189663539 hasAuthorship W1189663539A5015046857 @default.
- W1189663539 hasAuthorship W1189663539A5017725600 @default.
- W1189663539 hasAuthorship W1189663539A5019502209 @default.
- W1189663539 hasAuthorship W1189663539A5022335574 @default.
- W1189663539 hasAuthorship W1189663539A5032337429 @default.
- W1189663539 hasAuthorship W1189663539A5033334328 @default.
- W1189663539 hasAuthorship W1189663539A5036762272 @default.
- W1189663539 hasAuthorship W1189663539A5037958863 @default.
- W1189663539 hasAuthorship W1189663539A5041017678 @default.
- W1189663539 hasAuthorship W1189663539A5049605524 @default.
- W1189663539 hasAuthorship W1189663539A5049963981 @default.
- W1189663539 hasAuthorship W1189663539A5050487837 @default.
- W1189663539 hasAuthorship W1189663539A5053060128 @default.
- W1189663539 hasAuthorship W1189663539A5059234004 @default.
- W1189663539 hasConcept C11960822 @default.
- W1189663539 hasConcept C150903083 @default.
- W1189663539 hasConcept C178790620 @default.
- W1189663539 hasConcept C184235292 @default.
- W1189663539 hasConcept C185592680 @default.
- W1189663539 hasConcept C202751555 @default.
- W1189663539 hasConcept C207001950 @default.
- W1189663539 hasConcept C2778484023 @default.
- W1189663539 hasConcept C55493867 @default.
- W1189663539 hasConcept C57992300 @default.
- W1189663539 hasConcept C62478195 @default.
- W1189663539 hasConcept C71240020 @default.